



Press Release

MediVision Medical Imaging Ltd.

☎ + (972) 4-989-4884

☎ + (972) 4-989-4883

✉ P.O. Box 45, Tabor building 4, Yokneam Elit 20692, Israel

✉ noam@medivision-ois.com

FOR IMMEDIATE RELEASE

MediVision sells 1 Million Shares of OIS Common Stock for \$ 1,800,000

Yokneam Elit, Israel, MediVision Medical Imaging Ltd. (Euro.NM: MEDV) a leading provider of ophthalmic digital imaging systems for the ophthalmology market, announced today (February 20, 2006) that it sold 1,000,000 of the Company's holdings in its American subsidiary, Ophthalmic Imaging Systems ("OIS" - OTCBB: OISI) to Wasatch Advisors for a total consideration of \$1,800,000 at a price of \$1.80 per share. As a result of the agreement, the public float of OIS share will increase to approximately 6.7 million shares or 41%.

As a result of this transaction, MediVision is expected to show a capital gain of above \$1,100,000 in the financial statements of the first quarter of 2006. Following this sale of OIS equity MediVision's current holding in OIS will be reduced to 59%.

Noam Allon President and Chief Executive Officer of MediVision said: "The sale of shares is part of capital raising activities, which have carried out continuously and focused primarily on strategic growth; the funds will provide us with additional working capital to support our business expansion. With this transaction and similar previous transactions, which we performed during 2004 and 2005, we succeeded in attracting to OIS institutional investors that possess a solid interest in small-cap equities. We believe it is an additional step towards increasing the awareness and interest of the investment community in OIS".

About Wasatch Advisors – Wasatch Advisors (www.wasatchadvisors.com), founded in 1975, is an investment advisor to institutional clients and to Wasatch Funds (www.wasatchfunds.com), a family of mutual funds specializing in small and mid cap companies. Wasatch Advisors manages more than \$10 billion in mutual funds and institutional account assets.

About MediVision

MediVision specializes in digital imaging devices for ophthalmic applications with an emphasis on diagnostics related to the eye retina. MediVision's products are designed to provide digital upgrades for a range of ophthalmic imaging systems, thus significantly enhancing imaging capability and providing its users with advanced diagnostic tools. The company has significant market share and is a market leader in the ophthalmic digital imaging field. The Company owns 59% interest in Ophthalmic Imaging Systems based in Sacramento, California, USA and 63% interest in CCS Pawlowski GmbH based in Jena, Germany.

This Release contains certain forward-looking statements and information relating to the Company that are based on the beliefs of the Management of the Company as well as assumptions made by and information currently available to the Management of the Company. Such statements reflect the current views of the Company with respect to future events, the outcome of which is subject to certain risks and other factors, which may be outside of the Company's control. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results of outcomes may vary materially from those described herein as projected, anticipated, believed, estimated, expected or intended.

End of message

For more information, please contact:

Noam Allon

President, Chief Executive Officer

Tel. +972-4-9894884

Fax +972-4-9894883

E-mail: noam@medivision-ois.com